Alaunos Therapeutics (TCRT) EBITDA Margin (2011 - 2025)
Alaunos Therapeutics (TCRT) reported EBITDA Margin of 30233.33% for Q4 2025, down 1135833.0% on a YoY basis from N/an in Q4 2024, and up 44.63% quarter-over-quarter from 54600.0% in Q1 2025.
Alaunos Therapeutics (TCRT) EBITDA Margin (2011 - 2025) Analysis & Trends
Alaunos Therapeutics has reported EBITDA Margin for 13 years, with the latest figure at 30233.33% in Q4 2025.
- For the quarter ending Q4 2025, EBITDA Margin fell 1135833.0% year-over-year to 30233.33%; the trailing twelve-month figure through Mar 2026 stood at 138166.67% (down 9653667.0% YoY), and the FY2025 full-year result was 84500.0%, down 3638000.0% from the prior year.
- EBITDA Margin for Q4 2025 stood at 30233.33%, up from 54600.0% in the prior quarter.
- The five-year high for EBITDA Margin was 283.89% in Q3 2022, with the low at 794900.0% in Q4 2023.
- Historically, EBITDA Margin has averaged 176127.99% across 5 years, with a median of 54600.0% in 2025.
- Annual changes were most pronounced in 2023 — EBITDA Margin sank 71743636 bps — and 2024, when it soared 77602500 bps.
- Alaunos Therapeutics' EBITDA Margin stood at 552550.0% in 2021, then soared by 86 bps to 77463.64% in 2022, then slumped by 926 bps to 794900.0% in 2023, then soared by 98 bps to 18875.0% in 2024, then sank by 60 bps to 30233.33% in 2025.
- The last three EBITDA Margin figures came in at 30233.33% (Q4 2025), 54600.0% (Q1 2025), and 18875.0% (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Alaunos Therapeutics | 4.31 Mn | 3.95 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -30,233.33% |
| Mar 31, 2025 | -54,600.00% |
| Dec 31, 2024 | -18,875.00% |
| Jun 30, 2024 | -29,150.00% |
| Mar 31, 2024 | -174,200.00% |
| Dec 31, 2023 | -794,900.00% |
| Jun 30, 2023 | -199,550.00% |
| Dec 31, 2022 | -77,463.64% |
| Sep 30, 2022 | -283.89% |
| Dec 31, 2021 | -552,550.00% |
| Sep 30, 2021 | -5,602.01% |
| Mar 31, 2018 | -11,093.15% |
| Dec 31, 2017 | -841.33% |
| Sep 30, 2017 | -818.40% |
| Jun 30, 2017 | -814.90% |
| Mar 31, 2017 | -874.45% |
| Dec 31, 2016 | -695.74% |
| Sep 30, 2016 | -682.98% |
| Jun 30, 2016 | -7,733.77% |
| Mar 31, 2016 | -611.48% |